MP-0317 is a recombinant protein commercialized by Molecular Partners, with a leading Phase I program in Anal Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MP-0317’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for MP-0317 is expected to reach an annual total of $17 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
MP-0317 Overview
MP-0317 is under development for the treatment of colorectal cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, cervical cancer, anal cancer, melanoma, pancreatic cancer, gastric cancer, endometrial cancer, urothelial/bladder cancer, head and neck squamous cell carcinoma, breast cancer, mesothelioma and cutaneous squamous cell carcinoma. The therapeutic candidate is a bi-specific protein that acts by targeting CD40 and fibroblast activating protein (FAP) which is expressed in stroma of many tumor cells. It is administered by intravenous route and developed based on designed ankyrin repeat proteins (DARPin) technology.
Molecular Partners Overview
Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration. It also develops drugs on DARPin base technology and other product candidates. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications. The company also provides clinical trial services and small protein therapies called Darpin therapeutics. It has partnership with a pharmaceutical company to strengthen drug platforms through in-house development, licensing and collaboration. Molecular Partners is headquartered in Zurich, Switzerland.
The company reported revenues of (Swiss Francs) CHF9.8 million for the fiscal year ended December 2021 (FY2021), an increase of 4.4% over FY2020. The operating loss of the company was CHF63.4 million in FY2021, compared to an operating loss of CHF58.3 million in FY2020. The net loss of the company was CHF63.8 million in FY2021, compared to a net loss of CHF62.8 million in FY2020.
The company reported revenues of CHF2.4 million for the third quarter ended September 2022, a decrease of 98.7% over the previous quarter.
For a complete picture of MP-0317’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.